| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The Oncology Institute, Inc.
27,924,611 Shares
Common Stock
Offered by the Selling Securityholders
This prospectus relates to the resale from time to time of up to an aggregate of 27,924,611 shares of our common stock, $0.0001 par value per share, or our common stock, by the selling securityholders identified in this prospectus, or collectively with any donees, pledgees, assignees, transferees or other successors-in-interest, the Selling Securityholders, consisting of (v) 12,006,510 shares of our common stock presently issued and outstanding, (x) 2,886,614 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants to purchase shares of our common stock held by certain Selling Securityholders, or the Pre-Funded Warrants, (y) 9,308,204 shares of our common stock issuable upon the exercise of outstanding common warrants to purchase shares of our common stock held by certain Selling Securityholders, or the Common Warrants, and, together with the Pre-Funded Warrants, the Warrants, and (z) 3,723,283 shares of our common stock issuable upon the conversion of shares of our Series A Common Equivalent Convertible Preferred Stock, or the Series A Preferred Stock, upon the satisfaction of specified conditions set forth in the agreements pursuant to which the common stock, Prefunded Warrants and Common Warrants offered hereby were issued. The Warrants may be exercised in whole or in part at the discretion of the holder, subject to the limitations set forth therein. This prospectus provides you with a general description of the securities.
Posted In: TOI
